ACTO Recognized as Luminary in Everest Group's Innovation Watch for Agentic AI in Life Sciences

ACTO Achieves Luminary Status in AI Innovation

On October 5, 2026, ACTO, a pioneering company at the interface of human intelligence and empathetic AI, received high acclaim as a Luminary in the Everest Group's Innovation Watch report. This recognition celebrates ACTO's innovative role-based SuperAgents and their ability to orchestrate across various platforms while adhering to the stringent demands of the Life Sciences sector.

The Everest Group's report evaluated 22 vendors in agentic AI, focusing on market maturity, ecosystem driving forces such as partnerships, and investments. In this assessment, ACTO's outcomes positioned them within the Luminary category, which comprises both the strongest performers and those driving significant innovation within the ecosystem.

As agentic AI emerges as a vital component for digital transformation in the Life Sciences sector, ACTO stands out by enhancing decision-making processes, automating workflows, and facilitating cross-system operations that enable a personalized approach to customer interactions.
Rohit K, Practice Director at the Everest Group, emphasized, ‘The emphasis has shifted from isolated AI applications to interconnected business platforms. These new systems effectively connect data, content, and workflows across roles.' He acknowledged ACTO's unique role-based approach, which integrates domain-specific SuperAgents with platform-wide orchestration and governance tailored to Life Sciences.

ACTO's AI strategy has been years in the making. The company began investing in AI in 2022, launching a AI-powered dialogue assistant, LAICA, specifically geared towards learning in the Life Sciences arena. This innovation laid the groundwork for the 2026 launch of ACTO's SuperAgents.

Parth Khanna, co-founder and CEO of ACTO, expressed his enthusiasm for this recognition: “To be named a Luminary by the Everest Group, alongside strategic partners like Veeva and Salesforce, validates our vision. We firmly believe that AI can fundamentally change how we operate in Life Sciences—not by replacing humans, but by empowering them.”

This recognition also validates the company’s efforts to create intelligent, interconnected workforces where human relationships and AI collaborate to achieve superior outcomes. ACTO has crafted a solution utilizing its Field Excellence Platform, designed specifically for the Life Sciences industry, which integrates AI-powered SuperAgents that collaborate across systems, delivering compliant and timely support.

By focusing on allowing customer-facing employees to spend less time navigating complex systems and more time fostering relationships with healthcare professionals, ACTO redefines how therapies reach patients post-approval.

This recently awarded Luminary status follows ACTO's entry earlier in 2026 into the Top 50 Pharmaceutical Technology Providers list from the Everest Group, underscoring the company’s ongoing commitment to AI-driven field excellence in Life Sciences. For those interested in learning more, comprehensive insights are available in the full report, which can be downloaded for free at the company's website.

To stay informed about ACTO's advancements, visit their official site or follow them on LinkedIn for the latest updates.

About The Everest Group

The Everest Group is a premier global research firm dedicated to helping leaders make informed business decisions. Their PEAK Matrix® assessments provide in-depth analysis and insights that enable companies to strategize effectively regarding global service providers, locations, and various market solutions.

About ACTO

ACTO is trusted by 14 of the top 50 pharmaceutical companies, emerging biotechs, and leading medical technology firms. Their goal is to redefine how therapies reach patients, leveraging human intelligence combined with empathetic AI to expedite product launch and improve field execution while enhancing customer engagement. Committed to upholding the highest regulatory standards, ACTO is FDA 21 CFR Part 11 validated and SOC 2 Type II certified. For more information, please visit www.acto.com.